Jimenez-Fonseca, P., Foy, V., Raby, S., Carmona-Bayonas, A., Macia-Rivas, L., Arrazubi, V., . . . Gallego, J. (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Citación estilo ChicagoJimenez-Fonseca, P., et al. The AGAMENON-SEOM Model for Prediction of Survival in Patients With Advanced HER2-positive Oesophagogastric Adenocarcinoma Receiving First-line Trastuzumab-based Therapy. 2023.
Cita MLAJimenez-Fonseca, P., et al. The AGAMENON-SEOM Model for Prediction of Survival in Patients With Advanced HER2-positive Oesophagogastric Adenocarcinoma Receiving First-line Trastuzumab-based Therapy. 2023.
Precaución: Estas citas no son 100% exactas.